Skip to main content
snıff
Canine Mendelian disease record

Intestinal Cobalamin Malabsorption (Discovered in the Border Collie; CUBN-related)

Intestinal Cobalamin Malabsorption (Discovered in the Border Collie; CUBN-related). Autosomal recessive. Observed in 8 of 266 breeds tested in the Sniff Atlas, with measured carrier frequencies drawn from 242,665 dogs (Donner 2023). Per-dog phenotype outcome depends on penetrance, modifiers, and environment; the carrier frequencies below describe variant prevalence, not disease incidence.

OMIA identifier
OMIA:001786-9615
Autosomal recessive
Source dataset
Sniff Atlas v1.0.1 / DOI
The human connection

A model of human Imerslund-Grasbeck syndrome type 1

This is the canine counterpart of Imerslund-Grasbeck syndrome type 1 in people. That makes affected dogs a naturally-occurring model of the human disease, and it is part of why studying dogs moves medicine forward for everyone. It does not mean your dog has the human disease. It means the two share an underlying biology.

In people, the disease is described as: An autosomal recessive disorder characterized by onset of megaloblastic anemia associated with decreased serum vitamin B12 (cobalamin, Cbl) in infancy or early childhood. Low molecular weight (LMW) proteinuria is frequently present, but sometimes occurs later and is usually mild or subclinical. Patients often present with vague symptoms, including failure to thrive, loss of appetite, fatigue, lethargy, and/or recurrent infections. Some patients may present later in childhood with neurologic abnormalities related to B12 deficiency, such as sensorimotor neuropathy and/or cognitive disturbances.

In humans it is also called: MGA-1, MGA1, Mga1, enterocyte cobalamin malabsorption, enterocyte intrinsic factor receptor, defect of.

Mapped from OMIA via the human disease's OMIM entry to the Mondo Disease Ontology (Monarch Initiative, CC-BY 4.0). Sniff renders this as a model-of link; the canine disease remains the subject of this page.

About this disease

From OMIA's curated record

Documented in OMIA (Online Mendelian Inheritance in Animals). This describes the disease as recorded in the published literature, not a prediction for any individual dog. As of 2026-06-03.

Summary

Intestinal cobalamin malabsorption is a metabolic disorder characterized by failure to thrive, neutropenia, decreased serum cobalamin (Cbl), and nonregenerative anemia. Other signs include chronic inappetance, megaloblastic changes of the bone marrow, methylmalonic aciduria, and homocysteinemia. This phenotype can be caused by either mutations in the AMN or CUBN genes (locus heterogeneity). See also OMIA:001791-9615. Adapted from the corresponding entry by John Fyfe in [OMIA:000565-9615].

Clinical features

Signs begin around 6 to 12 weeks of age, and include failure to thrive and chronic inappetance. Affected animals also demonstrate neutropenia with hypersegmentation, nonregenerative anemia with anisocytosis and poikilocytosis, megaloblastic changes of the bone marrow, decreased serum Cbl concentrations, methylmalonic aciduria, and homocysteinemia. These animals have normal renal function, but low-molecular weight urinary protein excretion (Fyfe et al., 1991).

Molecular genetics

Whole genome re-sequencing of one affected Border Collie revealed 17 non-synonymous variants in the critical interval. Two of these variants were perfectly associated with intestinal cobalamin malabsorption in Border Collies. Based on the known functions of the corresponding genes the CUBN:c.8392delC frameshift variant is most likely causative for intestinal cobalamin malabsorption in Border Collies. This variant causes a premature stop codon in the open reading frame of cubilin (p.Gln2798Argfs*3) and is predicted to represent a complete loss of function allele (Owczarek-Lipska et al. 2013). CUBN and AMN form a transmembrane protein complex termed "cubam", which is essential in the uptake of cobalamin from the intestinal lumen. A defect in one of these two proteins therefore leads to intestinal cobalamin malabsorption. Other independent mutations in either the CUBN or the AMN gene very likely are responsible for this phenotype in other dog breeds. By sequencing CUBN as a very strong positional candidate gene (see Mapping section), Fyfe et al. (2013) identified the same mutation (c.8392delC; p. Gln2798Argfs*3) in their Border Collie families. Erles et al. (2018) reported "Systemic Scedosporium prolificans infection in an 11-month-old Border collie with cobalamin deficiency secondary to selective cobalamin malabsorption" due to homozygosity for the c.8392delC variant. By comparing sequence of the two candidate genes (AMN and CUBN) from the CanFam 3.1 reference genome assembly with sequence of the same two genes from the 15x whole-genome sequencing (WGS) of an affected Beagle, Drögemüller et al. (2014) identified "a single-base-pair deletion at Chr2:19,796,293 compared with the CanFam 3.1 reference genome assembly . . . . The variant lies within exon 8 of the CUBN gene and represents a frameshift mutation leading to an early premature stop codon (c.786delC). The predicted protein from the mutant allele contains <10% of the amino acids from the wild-type CUBN (p.Asp262Glufs*47). Thus, the identified variant most likely represents a complete loss-of-function allele." Fyfe et al. (2014) reported the same c.786delC mutation in affected Beagles, as did Kook et al. (2014; J Vet Intern Med and J Small Anim Pract) in a single affected Beagle. Fyfe et al. (2018): "Whole genome sequencing of two affected Komondor dogs of unknown relatedness and one parent and a clinically-normal littermate of an affected dog revealed a pathogenic single-base change in the CUBN intron 55 splice donor consensus sequence (NM_001003148.1: c.8746 + 1G > A) that was homozygous in affected dogs and heterozygous in the unaffected parents. Alleles of the variant co-segregated with alleles of the disease locus in the entire family and all more distantly-related sporadic cases. . . . This variant obliterates a splice donor consensus sequence in intron 55, predicting an abnormal RNA splicing pattern, and was thereby considered pathogenic. We confirmed the variant in all 6 affected Komondors by Sanger sequencing". Sancho et al. (2020) reported a most interesting example of an affected Beagle crossbred dog that turned out to be a compound heterozygote of the Beagle likely causal variant (c.786delC) and the Border Collie likely causal variant (c.8392delC). In other words, a genotype comprising these two deleterious variants resulted in similar clinical signs to homozygosity for either variant.

Pathology

In normal dogs, Cbl is ingested in the diet and binds to intrinsic factor, a glycoprotein made by the gastric mucosa and the pancreatic duct epithelium. The complex of intrinsic factor (IF) and Cbl is absorbed through binding receptors on enterocytes in the distal jejunum and ileum. Signs of intestinal cobalamin malabsorption are due to absence of receptors for the IF-Cbl complex at the brush border (Fyfe et al., 1991). Dogs are born with cobalamin stores, but they are rapidly used up during postnatal growth unless replaced from the diet. This is when signs become apparent (Fyfe et al., 1991).

Prevalence

At the time of mutation discovery Owczarek-Lipska et al. (2013) estimated the carrier frequency of the CUBN:c.8392delC defect at 6% in a cohort of 203 European Border Collies. Drögemüller et al. (2014) estimated the carrier frequency of the Beagle mutation (c.786delC) to be 9%. Mizukami et al. (2016) reported the frequency of the c.8392delC allele as 0.015 in 500 Border collies in Japan. Fyfe et al. (2018): "A population study using a simple allele-specific DNA test indicated mutant allele frequencies of 8.3 and 4.5% among North American and Hungarian Komondors, respectively."

History

The phenotype can be caused by either mutations in the AMN gene [OMIA:000565-9615] or the CUBN gene [this entry]. He et al (2003 & 2005) mapped and identified two independent AMN mutations in Australian Shepherds and Giant Schnauzers [OMIA 000565-9615]. More recently, Owczarek-Lipska et al. (2013) identified a frameshift mutation in the CUBN gene as cause for inestinal cobalamin malabsorption in the Border Collie.

Genetic testing

Genetic testing for the causative mutation is available. Genetic testing is recommended to confirm the clinical diagnosis in suspected cases. Genetic testing is also recommended for breeding animals to avoid the accidental mating of two carriers, which might lead to affected offspring.

Human analog

OMIA links this condition to its human counterpart in OMIM (Mendelian Inheritance in Man), the place to read across to the deeper human literature for the same biology.

Source: OMIA (Nicholas, Tammen & the Sydney Informatics Hub), entry OMIA:001786-9615, doi:10.25910/2AMR-PV70 (CC-BY 4.0).

The evidence

Published references

The peer-reviewed papers behind this disease, curated by OMIA. Starred entries are OMIA-designated landmark papers. Showing 6 of 24.

  1. Imerslund-Grasbeck syndrome in a cross-breed dog. · J Small Anim Pract · 2020 · PMID 33022748

References curated by OMIA (Nicholas, Tammen & the Sydney Informatics Hub), doi:10.25910/2AMR-PV70 (CC-BY 4.0). Full list at the OMIA entry.

Predict a litter

Set each parent's status for Intestinal Cobalamin Malabsorption (Discovered in the Border Collie; CUBN-related) and see the odds for their puppies. Single recessive variant, exact Mendelian math.

Parent A
Parent B
NNClear
NmCarrier
NmCarrier
mmAffected
Clear25%
Carrier50%
Affected25%

These are the genetic odds for one known variant, not a promise: a real litter varies around them, and penetrance or other genes can change whether the condition ever appears. Use it to avoid pairing two carriers and to keep a line healthy, not to engineer a dog. Inheritance mode per OMIA.

Your breed

See what Intestinal Cobalamin Malabsorption (Discovered in the Border Collie; CUBN-related) looks like in your dog's breed.

Carrier frequency by breed

Top 7 well-sampled breeds (n ≥ 50)

Maximum per breed across variants in the Donner 2023 cohort, with . The list below is split into well-sampled breeds (n ≥ 50 tested) and small-sample breeds (n < 50, where the Wilson CI typically spans more than 20 percentage points and frequencies should not be compared directly to the well-sampled entries). Frequencies are population-level, not per-litter or per-line.

0%3%5%
Border Collie3.6% · n 6,714
Beagle1.1% · n 5,292
Australian Shepherd<0.1% · n 2,296
Australian Cattle Dog<0.1% · n 982
Miniature American Shepherd<0.1% · n 1,476
German Shepherd<0.1% · n 15,648
n = 75,201 dogs · Donner et al. 2023 carrier-screening cohort · Sniff Atlas
Each bar is one well-sampled breed; the whisker is its Wilson 95% CI, and fainter bars have wider intervals. Frequencies are population-level, not per-litter. Carrier status for Intestinal Cobalamin Malabsorption (Discovered in the Border Collie; CUBN-related) is measured; phenotype outcome depends on penetrance and modifiers.
▸ Full table with Wilson 95% confidence intervals
Breed Carrier frequency n tested
Border Collie 3.6% 6,714
Beagle 1.1% 5,292
Australian Shepherd <0.1% 2,296
Australian Cattle Dog <0.1% 982
Miniature American Shepherd <0.1% 1,476
German Shepherd <0.1% 15,648
American Staffordshire Terrier <0.1% 42,793
▸ Also observed in 1 small-sample breed (n < 50)

Frequencies in this section are statistical estimates with wide Wilson 95% confidence intervals (typically >20 percentage points). Treat these as "carriers observed but the true population frequency is not yet measurable" rather than as comparable to the well-sampled entries above.

Breed Estimate n tested
Komondor 17.9% 14

258 additional breeds in the Donner 2023 cohort were tested but showed no carriers.

Penetrance

From genotype to phenotype

Carrier status is not the same as disease status. Penetrance is the fraction of at-risk dogs that develop the phenotype. The Donner 2023 S4 table tracks this for 1 variant(s) underlying this disease in the cohort.

At-risk dogs evaluated
5
Phenotype confirmed
1
Penetrance range
not yet quantifiable

Fewer than 20 at-risk dogs evaluated; too few to state a penetrance figure.

Predicted disease relevance at the per-dog level is UNPROVEN. The carrier frequency is measured; phenotype outcome is governed by penetrance, environment, and modifier loci. Consult a veterinarian for clinical interpretation.

How to cite this record

Citations

If you use this record in published work, cite the Sniff Atlas (the published dataset that carries the breed-level carrier frequencies) and the upstream sources:

  • Sniff Atlas v1.0.1 for the per-breed carrier frequencies:

    Gehring, M. (2026). Sniff Atlas v1.0.1. Zenodo. https://doi.org/10.5281/zenodo.20566358. CC-BY 4.0.

  • OMIA for the disease definition, inheritance, and gene assignment:

    Nicholas, F. W., & Tammen, I. (2024). OMIA. Sydney Informatics Hub, The University of Sydney. https://doi.org/10.25910/2AMR-PV70. Entry: OMIA:001786-9615.

  • Donner et al. 2023 for the breed × variant carrier-frequency cohort:

    Donner, J., Freyer, J., Davison, S., Anderson, H., Blades, M., Honkanen, L., et al. (2023). Genetic prevalence and clinical relevance of canine Mendelian disease variants in over one million dogs. PLOS Genetics, 19(2), e1010651. https://doi.org/10.1371/journal.pgen.1010651.

Full citation formats (BibTeX, RIS, CITATION.cff) at sniff.world/cite.

Related

Related

Last updated
Sources: Sniff Atlas v1.0.1 · OMIA OMIA:001786-9615 · Donner et al. 2023